Lung cells stay young by ignoring inflammation
Some cells in your body are shielded from your own immune response.
Researchers discovered in fruit flies how terminal tracheal cells, the final branches of the airway system, hold a special status within the immune system. They are immune-privileged: they do not respond to bacterial infections, while surrounding airway cells do.
The reason turned out to be straightforward. These cells lack a specific receptor (PGRP-LC) through which bacterial fragments are normally detected. This prevents activation of the immune signaling cascade (the Imd pathway). The study, published in eLife, shows that this is not a random gap but a conserved feature of this cell group.
Inflammation and structure conflict
Why is this protective? Terminal tracheal cells must continuously change shape in response to oxygen shortage or nutrient changes. That plasticity is driven by the protein FoxO. But immune system activation uses exactly the same protein, and that leads to cell death and loss of branching.
When researchers artificially added the immune receptor to these cells, the result was striking: the cells lost their branches, became damaged, and died. The damage could be prevented by switching off FoxO or the signaling protein AP-1.
What this tells us about aging
In longevity research, the tension between inflammation and cellular plasticity is a recurring theme. As tissues age, chronic low-grade inflammation increases (inflammaging). That inflammation disrupts the ability of cells to adapt. This study provides a concrete molecular example of how that conflict operates: the same transcription factor that enables flexibility is also recruited during immune activation, and those two functions are incompatible.
Whether this principle applies to human lung cells has not yet been investigated. But the evolutionarily conserved role of FoxO makes it a relevant hypothesis for further research into lung aging and tissue plasticity.